 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Olatoyosi Odenike and Anand Patel.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.778 |
|
|
|
-
Patel AA, Cahill K, Saygin C, Odenike O. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271.
Score: 0.959
-
Patel AA, Odenike O. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
Score: 0.933
-
Patel AA, Odenike O. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.933
-
Patel AA, Cahill K, Charnot-Katsikas A, Liu H, Gurbuxani S, Thirman M, Kosuri S, Artz AS, Larson RA, Stock W, Segal J, Odenike O. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.895
-
Carll T, Patel A, Derman B, Hyjek E, Lager A, Wanjari P, Segal J, Odenike O, Fidai S, Arber D. Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928.
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|